Ravi Kumar Nagiri

The paper develops a humanized neuroimmune model to study tauopathy and identifies microglial and lncRNA mechanisms that protect neurons.

This study identifies cGAS as a key mediator of TDP-43 pathology in ALS and shows that its inhibition reduces RNA splicing defects and neurodegeneration.

This study identifies cGAS-mediated IFN-I signaling as a driver of disease progression in drug-refractory epilepsy, showing that targeting cGAS reduces epileptic phenotypes and inflammation.

The paper identifies a potent human cGAS inhibitor through high-throughput screening and SAR analysis, showing sub-micromolar activity and partial inhibition of cGAMP levels.